NovoCure Ltd. (NVCR)
Summary
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 65 | $5,385.25 | $1,147.85 | -$4,237.4 | -78.69% |
 Curtis Ellergodt Rothschild Investment LLC | 192 | $3,077.76 | $3,384 | $306.24 | 9.95% |
| PN Peter Nicholson First Bancorp Inc. /ME/ | 2,500 | $38,700 | $44,048 | $5,348 | 13.82% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 265 | $3,424.96 | $4,690.5 | $1,265.54 | 36.95% |
| NA Nizar Araji National Bank Of Canada /FI/ | 483 | $5,893.17 | $7,913.95 | $2,020.78 | 34.29% |
NovoCure Ltd. (NVCR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NovoCure Ltd. ever had a stock split?
NovoCure Ltd. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Frank Leonard CEO | NASDAQ (NGS) Exchange | G6674U108 CUSIP |
| CH Country | 1,605 Employees | - Last Dividend | - Last Split | 2 Oct 2015 IPO Date |
Overview
NovoCure Limited is a pioneering oncology company that specializes in the development, manufacture, and commercialization of its innovative tumor treating fields (TTFields) devices for the treatment of various solid tumor cancers. Founded in 2000, NovoCure maintains a strong international presence with operations in the United States, Germany, Japan, Greater China, and other global markets. The company is headquartered in Saint Helier, Jersey, highlighting its global reach and commitment to advancing cancer treatment worldwide. NovoCure's groundbreaking approach focuses on utilizing TTFields technology to target cancer cells, offering a novel treatment option beyond traditional methods. With ongoing clinical trials aimed at expanding the applications of TTFields, NovoCure continues to explore the potential of its technology in treating a wide range of cancers, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Products and Services
- Optune Gio:
- Optune Lua:
Optune Gio is one of NovoCure's flagship TTFields devices, designed specifically for the treatment of glioblastoma, a highly aggressive form of brain cancer. This device represents a significant advancement in the field of oncology, offering a non-invasive treatment option that utilizes low-intensity electric fields to disrupt cancer cell division and growth. By targeting glioblastoma cells while sparing healthy tissue, Optune Gio offers a promising treatment alternative for patients with this challenging condition.
Optune Lua is another innovative TTFields device offered by NovoCure, tailored for the treatment of malignant pleural mesothelioma, a rare cancer linked to asbestos exposure that affects the lining of the lungs. Like Optune Gio, Optune Lua employs TTFields technology to selectively target cancer cells, aiming to inhibit their proliferation and induce cell death. This device provides a critical option for mesothelioma patients, for whom treatment options are often limited and prognosis is typically poor.
